ArticleThe FEBS journal2025
Studies of the membrane-bound flavocytochrome MsrQ flavin mononucleotide (FMN)-binding site reveal an unexpected ubiquinone cofactor.
Article in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The methionine sulfoxide reductase PQ system (MsrPQ) is a newly identified type of bacterial methionine sulfoxide reductase (Msr) involved in the repair of periplasmic methionine residues that have been oxidized by hypochlorous acid. MsrP, which carries out the Msr activity, is a molybdoenzyme located in the periplasm, whereas MsrQ, an integral membrane-bound flavohemoprotein, specifically transfers electrons to MsrP to drive catalysis. MsrQ belongs to an important superfamily of heme-containing membrane-bound proteins, which includes the eukaryotic NADPH oxidases (NOX) and six-transmembrane epithelial antigen of the prostate (STEAP) ferric reductases. Like STEAP, and in addition to a b-type heme, MsrQ contains a flavin cofactor [flavin mononucleotide (FMN)], which mediates electron transfer from a cytosolic NADH oxidoreductase to the heme, and subsequently to MsrP. In this study, we characterized the FMN-binding site of MsrQ using an AlphaFold model, identifying R77 and R78 residues as potentially critical for FMN stabilization. The R77A and R78A mutations result in the complete loss of the FMN cofactor, showing that both residues are essential for FMN binding. Surprisingly, electron paramagnetic resonance (EPR) spectroscopy and biochemical analysis of the mutants revealed the presence of a ubiquinone (UQ) cofactor associated with MsrQ, independently of the binding of FMN. The mid-point redox potentials of the MsrQ heme and FMN cofactors, measured through redox titration and cyclic voltammetry experiments, contradict the previous assumption that UQ serves as the electron donor for MsrQ. Instead, our data suggest that UQ may function as an electron acceptor for the reduced form of MsrQ. We propose that UQ bound to MsrQ could act as a protective mechanism when MsrP substrate is limiting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.